Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Durvalumab|DRUG: Trastuzumab|DRUG: Pertuzumab
Sponsor: The Methodist Hospital Research Institute
Collaborators: AstraZeneca